Citigroup Lowers Health Catalyst (NASDAQ:HCAT) Price Target to $10.00

Health Catalyst (NASDAQ:HCAT) had its price target trimmed by Citigroup from $10.50 to $10.00 in a report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts also recently weighed in on HCAT. Stephens raised their target price on Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research report on Thursday, November 14th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a research report on Wednesday. Royal Bank of Canada increased their price target on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Finally, Piper Sandler reissued an “overweight” rating and set a $12.00 target price (up previously from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.45.

Health Catalyst Stock Performance

NASDAQ HCAT opened at $6.89 on Friday. Health Catalyst has a twelve month low of $5.42 and a twelve month high of $11.41. The stock has a 50-day moving average of $7.79 and a 200 day moving average of $7.52. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $419.24 million, a price-to-earnings ratio of -5.10 and a beta of 1.36.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.22) EPS. Sell-side analysts anticipate that Health Catalyst will post -0.33 EPS for the current fiscal year.

Insider Activity at Health Catalyst

In related news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Monday, January 6th. The stock was sold at an average price of $7.51, for a total value of $39,119.59. Following the completion of the transaction, the chief operating officer now directly owns 91,253 shares in the company, valued at approximately $685,310.03. This trade represents a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $8.94, for a total value of $67,050.00. Following the completion of the transaction, the insider now owns 236,950 shares of the company’s stock, valued at approximately $2,118,333. This trade represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 76,051 shares of company stock worth $612,614. Company insiders own 2.50% of the company’s stock.

Institutional Trading of Health Catalyst

Institutional investors have recently bought and sold shares of the business. Quest Partners LLC purchased a new stake in Health Catalyst during the 3rd quarter worth about $34,000. Quarry LP lifted its holdings in Health Catalyst by 59.4% during the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after buying an additional 2,610 shares during the last quarter. nVerses Capital LLC purchased a new stake in Health Catalyst during the 3rd quarter worth about $59,000. Quadrature Capital Ltd purchased a new stake in Health Catalyst during the 3rd quarter worth about $84,000. Finally, Mackenzie Financial Corp purchased a new stake in Health Catalyst during the 2nd quarter worth about $70,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.